scispace - formally typeset
E

Elias Toubi

Researcher at Technion – Israel Institute of Technology

Publications -  164
Citations -  8565

Elias Toubi is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Autoantibody & Autoimmunity. The author has an hindex of 45, co-authored 164 publications receiving 7667 citations. Previous affiliations of Elias Toubi include Bar-Ilan University & San Diego State University.

Papers
More filters
Journal ArticleDOI

The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.

TL;DR: This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms, and outlines evidence-based diagnostic and therapeutic approaches for the different subtypes ofUrticaria.
Journal ArticleDOI

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.

Torsten Zuberbier, +48 more
- 01 Jul 2018 - 
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Journal ArticleDOI

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Marco Cicardi, +59 more
TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.
Journal ArticleDOI

Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients

TL;DR: This data indicates that continuation of an aggressive treatment with cyclosporine A for chronic urticaria is a viable option and may even be a viable treatment option for some patients with severe CU.